AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-30782160_ITM" title="Facts and information about Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007.">Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007.

PR Newswire

| May 16, 2007 | COPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

-- Data from Phase III pivotal trial demonstrate safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD --

NAPA, Calif., May 16 /PRNewswire/ -- Dey, L.P. announced that two clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on Sunday, May 20, at the Moscone Center in San Francisco. The presentations will detail Phase III clinical data demonstrating the safety and efficacy of Perforomist(TM) (formoterol fumarate) Inhalation Solution, approved on May 11 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

 
  For those attending ATS, the two presentations are available as follows: 
 
  -- "Nebulized Formoterol is an Effective Bronchodilator and Improves the 
     Quality of Life for COPD Patients," Poster Board #A10, ...

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation...: Press release article from: PR Newswire May 11, 2007 700+ words
...worldwide use. Perforomist(TM) Inhalation Solution is the first and only FDA...fumarate, Perforomist(TM) Inhalation Solution offers a new treatment...nebulizing with Perforomist(TM) Inhalation Solution twice a day - once in the...


Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol...: Press release article from: PR Newswire October 8, 2007 700+ words
...companies. Perforomist(TM) Inhalation Solution is indicated for long...experience. Perforomist(TM) Inhalation Solution is the first and only FDA...helpful that Perforomist(TM) Inhalation Solution offers a twice-daily...


New Data on Perforomist(TM) Inhalation Solution to be Presented at CHEST 2008.: Press release article from: PR Newswire October 24, 2008 700+ words
...with use of Perforomist(TM) Inhalation Solution - NAPA, Calif., Oct...results for Perforomist(TM) Inhalation Solution, twice daily via nebulization...MDI). Perforomist(TM) Inhalation Solution is approved for long...


Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be...: Press release article from: PR Newswire October 16, 2007 700+ words
...FDA) for Perforomist(TM) Inhalation Solution. The third presents results...concomitant use of Perforomist(TM) Inhalation Solution with tiotropium for the...of COPD. Perforomist(TM) Inhalation Solution is the first and only FDA...


Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at...: Press release article from: PR Newswire May 16, 2008 700+ words
...symptoms of using Perforomist(TM) Inhalation Solution, nebulized formoterol fumarate...research results. About Perforomist(TM) Inhalation Solution Indication Perforomist(TM) Inhalation Solution is indicated for the long-term...


Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol...: Press release article from: Business Wire October 8, 2007 700+ words
...NYSE: MYL). Perforomist[TM] Inhalation Solution is indicated for long-term, twice...United States. About Perforomist[TM] Inhalation Solution Indication Perforomist[TM] Inhalation Solution is indicated for the long-term...


Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged...: Newspaper article from: Clinical Trials Week November 10, 2008 700+ words
...treatment with Perforomist(TM) Inhalation Solution nebulized formoterol fumarate...twice-daily Perforomist(TM) Inhalation Solution, nebulized FFIS, compared...with either Perforomist(TM) Inhalation Solution or albuterol/ipratropium...


Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation...: Press release article from: PR Newswire May 20, 2007 700+ words
...found that Perforomist(TM) Inhalation Solution, a twice-daily, long...treatment between Perforomist(TM) Inhalation Solution and the active comparator...found that Perforomist(TM) Inhalation Solution was well tolerated, had...


Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement...: Press release article from: Business Wire June 28, 2007 700+ words
...evaluations of Perforomist[TM] Inhalation Solution included two clinical trials...treated with Perforomist[TM] Inhalation Solution 20 mcg/2 mL twice daily...showed that Perforomist[TM] Inhalation Solution 20 mcg/2 mL taken twice...


BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with...: Press release article from: Business Wire April 11, 2007 700+ words
...announced that BROVANA([TM]) brand arformoterol tartrate Inhalation Solution is now available by...to be approved as an inhalation solution for use with a nebulizer...includes XOPENEX([R]) Inhalation Solution and XOPENEX HFA...

For more facts and information, see all results

Source: HighBeam Research, Clinical Trial Data for Perforomist(TM) Inhalation Solution to be...